Abstract
Active injection drug use (IDU) is a behavior with the potential to offset healthcare engagement for those with HIV. At the Washington DC Veterans Affairs Medical Center, we identified 316 patients with a history of addiction during an 11-year period while actively engaged in routine visits to our HIV-primary care clinic. Among all IDU, active-abuse was determined in 141/316 (45 %). There were 120 clinically relevant blood stream infection (BSI) episodes. HIV/HCV co-infection (95 %) and use of antiretroviral therapy (76 %) were common at the time of BSI. The majority of BSIs occurred among those with active-IDU (72/120, 60 %). Active-IDU behavior was associated with more thrombotic disease (12 vs. 2 %, P = 0.001) and more frequent hospitalization (1.1/year ± 1.2 vs. 0.8/year ± 1.1, P = 0.03). When compared to drug-users with no active injection practices or those with remote IDU, active-IDU was associated with an increase in all-cause mortality (43 vs. 27 %, P = 0.003) and a decrease in age-adjusted survival (HR 1.7, CI 1.16–2.51, P = 0.007). Addressing addiction has the potential to impact avoidable medical complications and contribute to the continued, overall health of patients linked to HIV-care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Murray M, Hogg RS, Lima VD, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med. 2012;13(2):89–97.
Larsen MV, Omland LH, Gerstoft J, et al. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction. 2010;105(3):529–35.
Salter ML, Lau B, Go VF, et al. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis. 2011;53(12):1256–64.
Martin EG, Wang KH. Integrating substance abuse treatment into HIV care: missed opportunities in the AIDS Drug Assistance Program. J Acquir Immune Defic Syndr. 2013;62(4):421–9.
Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. AIDS. 2010;24(3):331–40.
Altice FL, Kamarulzaman A, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.
Floris-Moore M, Lo Y, Klein RS, et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34(3):331–7.
Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165(4):415–20.
Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;41(6):864–72.
Yehia BR, Fleishman JA, Wilson L, et al. HIV Research Network. Incidence of and risk factors for bacteraemia in HIV-infected adults in the era of highly active antiretroviral therapy. HIV Med. 2011;12(9):535–43.
Burkey MD, Wilson LE, Moore RD, et al. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med. 2008;9(10):858–62.
Acknowledgments
We wish to thank Peter Kokkinos, PhD and Bona Yoon, MPH for their assistance with manuscript review and preparation.
Disclosure
No competing financial interests exist for the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liappis, A.P., Laake, A.M. & Delman, M. Active Injection Drug-Abuse Offsets Healthcare Engagement in HIV-Infected Patients. AIDS Behav 19, 81–84 (2015). https://doi.org/10.1007/s10461-014-0757-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-014-0757-4